Biologics & ATMP regulatory strategy
Biologics and advanced therapies (ATMPs) present complex regulatory challenges including viral safety, cell bank qualification, endotoxin masking (LER), and raw material risk management. Authorities expect early regulatory pathway definition and robust scientific documentation. Our consulting services provide regulatory strategy for biologics, ATMP classification support, viral risk mitigation, and lifecycle compliance planning.
We help biotech and pharmaceutical companies navigate evolving regulatory frameworks with confidence.
Regulatory consulting for ATMP classification and development pathway strategy.
Viral safety and risk mitigation
Viral safety risk assessment and mitigation strategy for biologics and advanced therapies.
LER & pyrogenicity assessment
Evaluation of endotoxin masking (LER) and pyrogenicity risks in biologics manufacturing processes.
Cell bank qualification
Regulatory and scientific qualification strategy for Master and Working Cell Banks.
Raw material qualification for biologics and ATMPs
Risk-based qualification of raw materials for biologics in compliance with regulatory guidelines.